This promotional website is
intended for UK healthcare professionals only
This promotional website is intended for UK healthcare professionals only
- Adverse event reporting
- UK Prescribing Information
- Contact us
ENHERTU (trastuzumab deruxtecan) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens1
ENHERTU as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy1
Enhertu has a Conditional Marketing Authorisation
Prescribing Information can be accessed from the link at the top right of this website
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App store. Adverse events should also be reported to Daiichi Sankyo UK Pharmacovigilance on 0800 028 5122 or by email to pharmacovigilance@daiichi-sankyo.co.uk. As ENHERTU is a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.